MedTrace Logo

Maternal Brain Imaging in Opioid Use Disorder

NCT06008990 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2026-05-22

No results posted yet for this study

Summary

This research study aims to learn more about opioid use disorder (OUD) during pregnancy and how outcomes for pregnant women and their newborns can be improved. During pregnancy, people with OUD are prescribed medication-assisted therapy (MAT). The investigators are interested to know how the medication is broken down by the body during pregnancy and how effective it is. The investigators also want to learn if this medication and OUD have any effect on the different parts of the brain when compared to mothers without OUD.

Conditions

  • Opioid Use Disorder
  • Substance-Related Disorders
  • Substance Use
  • Pregnancy Related
  • Narcotic-Related Disorders
  • Buprenorphine Dependence

Interventions

DRUG

Buprenorphine

Pregnant mother must be taking Buprenorphine

DIAGNOSTIC_TEST

Maternal Brain MRI

Maternal Brain MRI obtained between 24-32 week gestation

OTHER

Blood Samples

During the MRI visit blood samples will be drawn: one hour prior to MRI, immediately before MRI, and one hour post MRI to test for Buprenorphine levels.

BEHAVIORAL

Questionnaires

Participants will answer questionnaires about their medical history, pregnancy, and substance use.

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Indiana University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-15
Primary Completion
2025-10-31
Completion
2025-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06008990 on ClinicalTrials.gov